Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Feb 5, 2007

Corium to Supply Durect with its Post-Shingles Pain Candidate

  • Durect entered into a long-term manufacturing and supply deal with Corium International for Durect’s Phase II post-shingles pain treatment. Transdur™-Bupivacaine is a transdermal pain patch.

    "Corium's flexible capabilities, expertise, and collaborative capacity in manufacturing transdermal products makes them an ideal partner for us," remarks James Brown, CEO of Durect.

    According to the agreement, Corium will provide Durect’s clinical and commercial supplies of Transdur-Bupivacaine on a worldwide basis.

    Transdur-Bupivacaine is intended to provide up to three days of pain relief for patients suffering from post-shingles pain, as compared to a wearing time limited to 12 hours with currently available patches. Durect has begun its Phase II program with a randomized, multicenter, double-blind, placebo-controlled, two-way crossover trial in approximately 50 patients with post-herpetic neuralgia, also known as post-shingles pain, to assess safety as well as the magnitude, duration, and characteristics of analgesic activity of Transdur-Bupivacaine.



Be sure to take the GEN Poll

Scientifically Studying Ecstasy

MDMA (commonly known as the empathogen “ecstasy”) is classified as a Schedule 1 drug, which is reserved for compounds with no accepted medical use and a high abuse potential. Two researchers from Stanford, however, call for a rigorous scientific exploration of MDMA's effects to identify precisely how the drug works, the data from which could be used to develop therapeutic compounds.

Do you agree that ecstasy should be studied for its potential therapeutic benefits?

More »